Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

A compartment model of VEGF distribution in blood, healthy and diseased tissues.

Stefanini MO, Wu FT, Mac Gabhann F, Popel AS.

BMC Syst Biol. 2008 Aug 19;2:77. doi: 10.1186/1752-0509-2-77.

2.

A two-compartment model of VEGF distribution in the mouse.

Yen P, Finley SD, Engel-Stefanini MO, Popel AS.

PLoS One. 2011;6(11):e27514. doi: 10.1371/journal.pone.0027514. Epub 2011 Nov 8.

3.

VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model.

Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS.

Am J Physiol Heart Circ Physiol. 2010 Jun;298(6):H2174-91. doi: 10.1152/ajpheart.00365.2009. Epub 2010 Apr 9.

4.

Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.

Nassehi D.

Dan Med J. 2013 Apr;60(4):B4626. Review.

PMID:
23651727
5.

Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle.

Mac Gabhann F, Popel AS.

Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H459-74. Epub 2006 Sep 15.

6.

Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches.

Mac Gabhann F, Popel AS.

PLoS Comput Biol. 2006 Dec 29;2(12):e180. Epub 2006 Nov 16.

7.

Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Vempati P, Popel AS, Mac Gabhann F.

Cytokine Growth Factor Rev. 2014 Feb;25(1):1-19. doi: 10.1016/j.cytogfr.2013.11.002. Epub 2013 Nov 27. Review.

8.

The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features.

Nieminen T, Toivanen PI, Rintanen N, Heikura T, Jauhiainen S, Airenne KJ, Alitalo K, Marjomäki V, Ylä-Herttuala S.

Biochim Biophys Acta. 2014 Jan;1840(1):454-63. doi: 10.1016/j.bbagen.2013.10.005. Epub 2013 Oct 8.

PMID:
24112971
9.

A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap.

Wu FT, Stefanini MO, Mac Gabhann F, Popel AS.

PLoS One. 2009;4(4):e5108. doi: 10.1371/journal.pone.0005108. Epub 2009 Apr 8.

10.

Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy.

Mac Gabhann F, Ji JW, Popel AS.

PLoS Comput Biol. 2006 Sep 22;2(9):e127. Epub 2006 Aug 3.

11.

Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models.

Wu FT, Stefanini MO, Mac Gabhann F, Popel AS.

Methods Enzymol. 2009;467:461-97. doi: 10.1016/S0076-6879(09)67018-X.

12.

Evidence for Pro-angiogenic Functions of VEGF-Ax.

Xin H, Zhong C, Nudleman E, Ferrara N.

Cell. 2016 Sep 22;167(1):275-284.e6. doi: 10.1016/j.cell.2016.08.054.

13.

Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model.

Mac Gabhann F, Popel AS.

Am J Physiol Heart Circ Physiol. 2005 Jun;288(6):H2851-60. Epub 2005 Feb 11.

14.

The presence of VEGF receptors on the luminal surface of endothelial cells affects VEGF distribution and VEGF signaling.

Stefanini MO, Wu FT, Mac Gabhann F, Popel AS.

PLoS Comput Biol. 2009 Dec;5(12):e1000622. doi: 10.1371/journal.pcbi.1000622. Epub 2009 Dec 24.

15.

Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise.

Ji JW, Mac Gabhann F, Popel AS.

Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3740-9. Epub 2007 Sep 21.

17.

Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies.

Finley SD, Engel-Stefanini MO, Imoukhuede PI, Popel AS.

BMC Syst Biol. 2011 Nov 21;5:193. doi: 10.1186/1752-0509-5-193.

18.

Chimeric VEGF-E(NZ7)/PlGF promotes angiogenesis via VEGFR-2 without significant enhancement of vascular permeability and inflammation.

Zheng Y, Murakami M, Takahashi H, Yamauchi M, Kiba A, Yamaguchi S, Yabana N, Alitalo K, Shibuya M.

Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2019-26. Epub 2006 Jun 22.

19.

Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability.

Plein A, Fantin A, Ruhrberg C.

Microcirculation. 2014 May;21(4):315-23. doi: 10.1111/micc.12124. Review.

20.

Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.

Shinkaruk S, Bayle M, Laïn G, Déléris G.

Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. Review.

PMID:
12678905

Supplemental Content

Support Center